SueWallSt notice cites Oct. 5 deadline in Replimune securities case
SueWallSt said Replimune investors who bought shares between Oct. 20, 2025, and April 10, 2026, face an Oct. 5, 2026 lead-plaintiff deadline in a pending securities class action.
A plaintiff-firm notice says Replimune investors may seek lead-plaintiff status in a securities class action tied to the company’s RP1 FDA filing and a later rejection from regulators.
SueWallSt published a PR Newswire notice on Aug. 13 reminding investors of an Oct. 5, 2026 lead-plaintiff deadline in a pending securities class action involving Replimune Group Inc., according to the notice. The reminder covers purchasers of Replimune securities between Oct. 20, 2025, and April 10, 2026.
The notice says the case centers on statements about Replimune’s RP1 biologics license application, or BLA, and the company’s response to prior FDA feedback. It says Replimune told investors its resubmission was a complete response to the agency’s deficiency letter and that commercial launch teams were ready.
It also says the FDA issued a Complete Response Letter on April 10, 2026, rejecting the RP1 BLA. The notice says the FDA wrote that study-design concerns had been communicated in earlier interactions but were not addressed. It adds that the agency said RPL-001-16 was not an adequate and well-controlled clinical investigation and that the resubmission relied on an early unplanned analysis representing 10% of planned enrollment, which the FDA described as insufficient to support an efficacy claim.
The notice says the complaint alleges Replimune and unnamed individual defendants made misleading statements, but the extracted text does not identify those people or include the underlying complaint, FDA letter or company filings. That limits independent verification of the allegations in the notice itself.
According to the notice, REPL shares fell from a class-period high of $10.73 on Dec. 8, 2025, to $1.70 on April 13, 2026. The notice says that was a decline of about $9.03 a share, or roughly 84%.
The notice quotes attorney Joseph E. Levi as saying that companies making specific promises have an obligation to disclose known risks tied to those projections. The text presents that as part of the plaintiff-firm’s pitch to investors rather than as a court finding.
Replimune’s disclosure practices and the FDA’s full reasoning are not included in the extracted source text. The notice says the lead-plaintiff deadline is Oct. 5, 2026, and that investors in the stated class period may seek to participate in the case.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()